Emcure Pharmaceuticals IPO GMP Today in the Grey Market is Not Available at The Moment. Investors are Advised to Closely Monitor Market Trends and consult Reliable Sources for the Most up-to-date Information. It is important to Exercise Caution and Conduct Thorough Research Before Making Any Investment Decisions.
About Emcure Pharmaceuticals IPO-
How Much GMP Price Emcure Pharmaceuticals IPO today?, live Grey Market Premium Kostak Rates today live Emcure Pharmaceuticals IPO Now. Subject To sauda Rate today, Emcure Pharmaceuticals IPO as of today Subject to sauda rates kostak.
Emcure Pharmaceuticals IPO is to open on 3 July, 2024. Emcure Pharmaceuticals is a Mainline IPO to Raise 19,365,346 shares (Approx ₹1,952.03 Cr) Via IPO. The Emcure Pharmaceuticals IPO Price Band is Fixed At ₹1008 Per Every Share With a IPO Lot Size of 14 Shares.
About Emcure Pharmaceuticals Data Like –
- Satish Mehta is the CEO of Emcure Pharmaceuticals and Emcure Pharmaceuticals was founded in the year 1981 and has just completed 39 years in operation.
- Emcure Pharmaceuticals are one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
- We are a research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled us to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada.
- Our competitive advantage in the domesti market stems from our differentiated product portfolio, which has allowed us to establish our presence in most of the major therapeutic areas, including gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/anti-neoplastics.
Emcure Pharmaceuticals IPO GMP With Per Lot Profit
| DATE | IPO GMP PRICE | EST LISTING PRICE |
|---|---|---|
| 10 July | ₹302 | ₹1310 |
| 9 July | ₹302 | ₹1310 |
| 8 July | ₹366 | ₹1374 |
| 7 July | ₹392 | ₹1400 |
| 6 July | ₹372 | ₹1380 |
| 5 July | ₹372 | ₹1380 |
| 4 July | ₹334 | ₹1342 |
| 3 July | ₹332 | ₹1340 |
| 2 July | ₹312 | ₹1320 |
| 1 July | ₹285 | ₹1293 |
| 30 June | ₹265 | ₹1273 |
| 29 June | ₹265 | ₹1273 |
| 28 June | ₹269 | ₹1277 |
Also Read : Emcure Pharmaceuticals IPO details, Date, Price, GMP, Review
Latest IPO GMP
We Update live GMP status of all upcoming IPOs every day until the IPO gets listed on the stock exchange. You can easily see the GMP price of all IPOs on our IPO GMP dashboard. We update IPO GMP performance regularly on Moneymintidea.com. You can easily get a rough idea of the GMP of all IPOs and what the listing price of the IPO is going to be.
IPO Grey Market Premium (GMP)
Before investing money in any IPO, one should pay more attention to the fact that the IPO GMP price is very volatile, if you are thinking of investing in Emcure Pharmaceuticals IPO by looking at the GMP price, then your decision may prove to be quite risky. Before investing in a new IPO, you should have good knowledge about the business of the company. It should be your decision whether to invest in Emcure Pharmaceuticals IPO or not and not by looking at the GMP price of the IPO.
Grey Market Premium (GMP) is the price at which an IPO is traded in an informal/unregulated manner before getting listed on the stock exchange. GMP price in the gray market reflects the price at which a company’s IPO is listed. Going to do. A good GMP premium/price gives you an indication of how much profit the IPO will make upon listing. Rather, if the GMP premium of an IPO is negative, then one should avoid investing money in that IPO.
Disclaimer:- The article here should not be construed as an offer to you to buy or sell based on any IPO / Gray Market Premium (GMP) or as advice in any way. The article here is written for informational and educational informational purposes only. This article should not be relied upon for investing in IPOs. Readers should consult a qualified financial advisor before making investment decisions.
Any reader making any investment decision based on the information published here does so entirely at his own risk. Investors should be aware that any investment in the equity market is subject to unpredictable market-related risks. The author does not intend to invest in this offering.
